Department of Developmental Biology and Cancer Research, Institute of Medical Research Israel-Canada, The Hebrew University- Faculty of Medicine, Jerusalem, Israel
Department of Developmental Biology and Cancer Research, Institute of Medical Research Israel-Canada, The Hebrew University- Faculty of Medicine, Jerusalem, Israel
Rachel Kalifa
Department of Developmental Biology and Cancer Research, Institute of Medical Research Israel-Canada, The Hebrew University- Faculty of Medicine, Jerusalem, Israel
Amatzia Dreifuss
Department of Developmental Biology and Cancer Research, Institute of Medical Research Israel-Canada, The Hebrew University- Faculty of Medicine, Jerusalem, Israel
Dina Rekler
Department of Developmental Biology and Cancer Research, Institute of Medical Research Israel-Canada, The Hebrew University- Faculty of Medicine, Jerusalem, Israel
Ariella Weinberg-Shukron
Medical Genetics Institute, Shaare Zedek Medical Center, the Hebrew University Hadassah Medical School, Jerusalem, Israel
Yuval Nevo
Bioinformatics Unit of the I-CORE Computation Center, The Hadassah Hebrew University Medical Center, Jerusalem, Israel
Tzofia Bialistoky
Department of Developmental Biology and Cancer Research, Institute of Medical Research Israel-Canada, The Hebrew University- Faculty of Medicine, Jerusalem, Israel
Victoria Moyal
Department of Developmental Biology and Cancer Research, Institute of Medical Research Israel-Canada, The Hebrew University- Faculty of Medicine, Jerusalem, Israel
Department of Developmental Biology and Cancer Research, Institute of Medical Research Israel-Canada, The Hebrew University- Faculty of Medicine, Jerusalem, Israel
Shira Leebhoff
Department of Developmental Biology and Cancer Research, Institute of Medical Research Israel-Canada, The Hebrew University- Faculty of Medicine, Jerusalem, Israel
David Zangen
Division of Pediatric Endocrinology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Department of Developmental Biology and Cancer Research, Institute of Medical Research Israel-Canada, The Hebrew University- Faculty of Medicine, Jerusalem, Israel
We recently identified a missense mutation in Nucleoporin107 (Nup107; D447N) underlying XX-ovarian-dysgenesis, a rare disorder characterized by underdeveloped and dysfunctional ovaries. Modeling of the human mutation in Drosophila or specific knockdown of Nup107 in the gonadal soma resulted in ovarian-dysgenesis-like phenotypes. Transcriptomic analysis identified the somatic sex-determination gene doublesex (dsx) as a target of Nup107. Establishing Dsx as a primary relevant target of Nup107, either loss or gain of Dsx in the gonadal soma is sufficient to mimic or rescue the phenotypes induced by Nup107 loss. Importantly, the aberrant phenotypes induced by compromising either Nup107 or dsx are reminiscent of bone morphogenetic protein (BMP signaling hyperactivation). Remarkably, in this context, the metalloprotease AdamTS-A, a transcriptional target of both Dsx and Nup107, is necessary for the calibration of BMP signaling. As modulation of BMP signaling is a conserved critical determinant of soma–germline interaction, the sex- and tissue-specific deployment of Dsx-F by Nup107 seems crucial for the maintenance of the homeostatic balance between the germ cells and somatic gonadal cells.